Yulduzkhan Dauytova, Zhamilya Zholdybay, Zh. Zhakenova, J. Amankulov, S. Baigulova
{"title":"Pet / ct评估淋巴瘤对治疗的反应","authors":"Yulduzkhan Dauytova, Zhamilya Zholdybay, Zh. Zhakenova, J. Amankulov, S. Baigulova","doi":"10.52532/2521-6414-2022-1-63-32-35","DOIUrl":null,"url":null,"abstract":"Relevance: PET/CT has become an integral part of the diagnostic algorithm in lymphoma patients since lymphomas actively accumulate 18F-FDG. The high accuracy of PET/CT in patients with certain lymphoma types allows effective use of this method in clinical practice \nfor diagnosis, staging, re-staging, evaluating the effectiveness of treatment, and determining further patient management tactics. \nThe study aimed to evaluate the PET/CT capacity in assessing lymphoma treatment effectiveness. \nMethods: We conducted a retrospective analysis of PET/CT 18F-FDG results in 109 patients with a verified lymphoma diagnosis. The \npatients underwent PET/CT examinations at “Orhun Medical” PET/CT center based in the JSC “Kazakh Institute of Oncology and Radiology” (Almaty, Kazakhstan). \nResults: According to PET/CT results in assessing the lymphoma treatment effectiveness, the stabilization of the process was achieved \nin 38.5% of cases, progression – in 33.03%, a partial metabolic response – in 18.35%, and a complete response – in 10.09% of cases. \nConclusion: PET/CT is the method of choice for evaluating the effectiveness of lymphoma treatment compared to other radiological \ntechniques. PET/CT is based on determining metabolic treatment response, not only on size indicators. It plays an essential role in different \nstages of lymphoma treatment, providing new opportunities for personalized treatment","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PET/CT IN ASSESSING THE LYMPHOMA RESPONSE \\nTO TREATMENT\",\"authors\":\"Yulduzkhan Dauytova, Zhamilya Zholdybay, Zh. Zhakenova, J. Amankulov, S. Baigulova\",\"doi\":\"10.52532/2521-6414-2022-1-63-32-35\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Relevance: PET/CT has become an integral part of the diagnostic algorithm in lymphoma patients since lymphomas actively accumulate 18F-FDG. The high accuracy of PET/CT in patients with certain lymphoma types allows effective use of this method in clinical practice \\nfor diagnosis, staging, re-staging, evaluating the effectiveness of treatment, and determining further patient management tactics. \\nThe study aimed to evaluate the PET/CT capacity in assessing lymphoma treatment effectiveness. \\nMethods: We conducted a retrospective analysis of PET/CT 18F-FDG results in 109 patients with a verified lymphoma diagnosis. The \\npatients underwent PET/CT examinations at “Orhun Medical” PET/CT center based in the JSC “Kazakh Institute of Oncology and Radiology” (Almaty, Kazakhstan). \\nResults: According to PET/CT results in assessing the lymphoma treatment effectiveness, the stabilization of the process was achieved \\nin 38.5% of cases, progression – in 33.03%, a partial metabolic response – in 18.35%, and a complete response – in 10.09% of cases. \\nConclusion: PET/CT is the method of choice for evaluating the effectiveness of lymphoma treatment compared to other radiological \\ntechniques. PET/CT is based on determining metabolic treatment response, not only on size indicators. It plays an essential role in different \\nstages of lymphoma treatment, providing new opportunities for personalized treatment\",\"PeriodicalId\":19480,\"journal\":{\"name\":\"Oncologia i radiologia Kazakhstana\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncologia i radiologia Kazakhstana\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52532/2521-6414-2022-1-63-32-35\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologia i radiologia Kazakhstana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52532/2521-6414-2022-1-63-32-35","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
PET/CT IN ASSESSING THE LYMPHOMA RESPONSE
TO TREATMENT
Relevance: PET/CT has become an integral part of the diagnostic algorithm in lymphoma patients since lymphomas actively accumulate 18F-FDG. The high accuracy of PET/CT in patients with certain lymphoma types allows effective use of this method in clinical practice
for diagnosis, staging, re-staging, evaluating the effectiveness of treatment, and determining further patient management tactics.
The study aimed to evaluate the PET/CT capacity in assessing lymphoma treatment effectiveness.
Methods: We conducted a retrospective analysis of PET/CT 18F-FDG results in 109 patients with a verified lymphoma diagnosis. The
patients underwent PET/CT examinations at “Orhun Medical” PET/CT center based in the JSC “Kazakh Institute of Oncology and Radiology” (Almaty, Kazakhstan).
Results: According to PET/CT results in assessing the lymphoma treatment effectiveness, the stabilization of the process was achieved
in 38.5% of cases, progression – in 33.03%, a partial metabolic response – in 18.35%, and a complete response – in 10.09% of cases.
Conclusion: PET/CT is the method of choice for evaluating the effectiveness of lymphoma treatment compared to other radiological
techniques. PET/CT is based on determining metabolic treatment response, not only on size indicators. It plays an essential role in different
stages of lymphoma treatment, providing new opportunities for personalized treatment